NICE Approves New Treatment for Chemotherapy-Resistant Ovarian Cancer, Offering Hope to Patients
The National Institute for Health and Care Excellence (NICE) has approved mirvetuximab soravtansine, a targeted therapy for platinum-resistant ovarian cancer, marking the first such approval in over two decades. This treatment is designed for women with certain gynaecological cancers that have stopped responding to standard chemotherapy. It specifically targets folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug binds to cancer cells and delivers the treatment directly, offering a new option for patients who have limited alternatives. Approximately 270 patients are expected to benefit in the first year, with numbers rising as access to testing increases. The treatment is administered via intravenous infusion and is noted for having fewer side effects and requiring fewer hospital visits compared to standard chemotherapy. 
